

GYVENIMO APRAŠYMAS

Atnaujinta 2024-01-25

Arvydas Laurinavičius

Gimimo data: 1963-10-14
Gimimo vieta: Vilnius
Kontaktai: tel. 8 699 920 45, el. p. lauar@vpc.lt



Išsilavinimas:

2006 Vilniaus universitetas, habilitacijos procedūra, med. dr. (HP)
1996-1997 Harvardo universitetas (JAV), specializacija (*fellowship*) inkstų patologijoje
1989-1992 Maskvos Medicinos akademija (Rusija), medicinos mokslų daktaras (patologija)
1981-1987 Vilniaus universitetas, Medicinos fakultetas, gydytojas pediatras

Darbinė veikla:

2023- Patologijos ir teismo medicinos katedros vedėjas, Vilniaus universitetas, Medicinos fakultetas, Biomedicinos mokslų institutas
2016-2023 Patologijos, teismo medicinos ir farmakologijos katedros vedėjas, Vilniaus universitetas, Medicinos fakultetas, Biomedicinos mokslų institutas
2007- Profesorius, Vilniaus universitetas, Patologijos, teismo medicinos ir farmakologijos katedra
2003-2007 Docentas, Vilniaus universitetas, Patologijos ir teismo medicinos katedra
1993- Direktorius, gydytojas patologas konsultantas, Valstybinis patologijos centras, VULSK filialas (2011-)
1992-2003 Lektorius, Vilniaus universitetas, Patologijos ir teismo medicinos katedra
1987-1992 Stažuotojas-tyrėjas, Vilniaus universitetas, Patologijos ir teismo medicinos katedra

Stazuotės:

2019 Marine Biological Laboratory, Woods Hole, JAV
2018 Marine Biological Laboratory, Woods Hole, JAV
2018 University of California Davis, Sacramento, JAV
2017 AstraZeneca, Cambridge, JK
2016 AstraZeneca, Cambridge, JK
2015 TissueGnostics, Viena, Austrija
2011 Kanų vėžio centras (Prancūzija), ES COST projektas EuroTelepath
1999 Harvardo universitetas, *Brigham and Women's* ligoninė, JAV
1995 Harvardo universitetas, Molekulinio autoimunizacijos laboratorija, Brigham and Women's ligoninė, JAV
1994 Iliojaus universitetas, *Lutheran General* ligoninė, JAV

Licencijos:

2005 Gydytojo patologo licencija Nr. MPL-06474, aukščiausios kategorijos gydytojas patologas

Kitos profesinės ir visuomeninės pareigos, dalyvavimas komitetuose ir komisijose:

2013-2014 Narys, darbo grupė Biobankų įstatymo projektui parengti, LR Sveikatos apsaugos ministerija
2011-2012 Narys, darbo grupė Biobankų įstatymo projektui parengti, LR Seimo Sveikatos reikalų komitetas
2011- Narys, Valdymo taryba, *International Academy of Digital Pathology*
2011- Narys, Redakcinė kolegija, *Diagnostic Pathology* (ISI žurnalas)
2011- Pirmininkas, projekto priežiūros komitetas, „Jungtinio inovatyvios medicinos centro įsteigimas“
2011- Narys, VMTI Inovatyvios medicinos centro mokslo taryba
2011- Narys, Valdymo taryba, Santaros slėnio asociacija
2008- Viceprezidentas, Inovatyvių medicinos technologijų ir biofarmacijos asociacija
2008- Narys, Redakcinė kolegija, *Medicina* (ISI žurnalas)
2007- Pirmininkas, Laboratorijos duomenų saugojimo ir apsaugos standartų komitetas, SAM
2007-2009 Pirmininkas, IHTSDO Mokslo ir inovacijų komitetas
2007- Narys, IHTSDO, Valdymo taryba, SAM
2006-2007 Vadovas, darbo grupė Lietuvos stojimui į sistematizuotas medicinos nomenklatūros standartų plėtros organizaciją (*International Health Terminology Standards Development Organisation, IHTSDO*) pasirengti, SAM

2006-2007	Pirmininkas, darbo grupė, MN "Gydytojas patologas", SAM
2006-2011	Narys, „Lietuvos E. Sveikatos“ koordinavimo komitetas, SAM
2005-2006	Narys, „E. Sveikatos“ projekto priežiūros komitetas, SAM
2004-2009	Pirmininkas, koordinavimo taryba, Valstybės investicijų programa "Lietuvos patloginės anatomijos technikos ir technologijų atnaujinimo programa", SAM

Narystė ir pareigos profesinėse organizacijose:

2015-	Redakcinės komisijos narys, žurnalas "Pathology Informatics"
2014-2018	Pirmininkas, Biobank-LT – Lietuvos mokslo Biobankų konsorciumas.
2013-2020	Pirmininkas, SVIBI.LT – Lietuvos sveikatos informatikos ir bioinformatikos asociacija.
2011-2019	Valdybos narys, International Academy of Digital Pathology.
2001-2007	Viceprezidentas, Lietuvos Nefrologijos, dializės ir transplantacijos asociacija
1998-	Afilijuotas narys, Amerikos Patologų kolegija (<i>College of American Pathologists</i>)
1996-	Narys, Tarptautinė Nefrologų draugija (<i>International Society of Nephrology</i>)
1995-1997	Narys, Europos Patologų draugija (<i>European Society of Pathology</i>)

Mokslo interesų sritys:

Inkstų patologija, skaitmeninė patologijos vaizdo analizė, patologijos informatika, sveikatos informacinių sistemų standartai, biologinių žymenų tyrimai vėžio audiniuose, daugiamačė biožymenų raiškos analizė

Pedagoginė veikla:

	Vilniaus universitetas, Medicinos fakultetas:
2000-	VU doktorantūros vadovas (11) ir konsultantas (2), disertacijų gynimo komitetų narys, pirmininkas, oponentas
1998	Diagnostinės patologijos elektyvinis kursas medicinos studentams
1995-	Patloginės anatomijos kurso vadovas, paskaitos ir pratybos
1993-1994,	Inkstų patologijos gydytojų tobulinimo kursai
2008	
1992	Hospitalinės patologijos kursas, medicinos studentai
1992-	Patloginės anatomijos pratybos ir paskaitos
1987-1989	Patloginės anatomijos pratybos
	Maskvos Medicinos akademija:
1990-1991	Patloginės anatomijos pratybos
	Harvardo universitetas:
1996-1997	Inkstų patologijos seminarai medicinos studentams, patologijos rezidentams, nefrologijos internams ir stažuotojams

Konferencijos, organizavimas/pranešimai:

1. *Digital transformation in nephropathology*, 5th International Renal Pathology Conference, Zagrebas, Kroatija, 2023.
2. *Digital and Computational Pathology: Towards Augmented Intelligence*, Estonian Society of Oncologists conference, Talinas, Estija, 2022.
3. *Digital and Computational Pathology: Enabling Pathologists*, European Society of Pathology Academy, Genval, Belgija, 2022.
4. *Assessment of Glomerular Patterns of Injury by Machine Learning Methods*, European Congress on Digital Pathology (ECDP2022), Berlynas, Vokietija, 2022.
5. *Digital Data-Driven Kidney Pathology Assessment*, 59TH ERA CONGRESS (European Renal Association), Paryžius, Prancūzija, 2022.
6. *Digital Pathology Biomarkers for Breast Cancer*, ESO-ESP Online Digital Pathology Seminar, online, 2021.
7. *Histologic lymph nodes regression after preoperative chemotherapy as prognostic factor in non-metastatic advanced gastric adenocarcinoma*, 10th Congress of the Baltic Association of Surgeons, online, 2021.
8. *Intratatumoral heterogeneity and immune response in breast carcinoma*, 18th European Congress on Digital Pathology, online, 2021.
9. *Digital Intelligence for Tissue Pathology*, Molecular Diagnostics & Image Analysis Training School 2021, online, 2021.
10. *Pathology image analytics: going beyond visual*, Image Analysis Training School (IATS), Vine, Austrija, 2020
11. *Kidney Biopsy Diagnosis in Nephritic Syndrome*, Latvijos nefrologų asociacijos Susitikimas, Ryga, Latvija, 2020.
12. *Mining HALO for advanced spatial analytic*. 6th Digital Pathology & AI Congress. Londonas, JK, 2019.
13. *Histological findings in Fabry patients: interesting cases*. Tarptautinė mokslinė praktinė konferencija "1st Baltics Fabry Multidisciplinary Team (MDT) meeting. Vilnius, Lietuva, 2019.

14. *The Immunogradient of CD8+ cell density in the tumour-stroma interface zone predicts overall survival of patients with hormone receptor-positive invasive ductal breast carcinoma.* 31st European Congress of Pathology, Nica, Prancūzija, 2019.
15. *Prognostic value of CD8 Immunogradient indicators in tumour-stroma interface zone of colorectal cancer.* 31st European Congress of Pathology, Nica, Prancūzija, 2019.
16. *Deep Context Pathology for Precision Medicine.* 4th International Conference on Digital Pathology, Ciurichas, Šveicarija, 2019.
17. *Automated tumour-stroma interface zone CD8+ Immunogradient indicators predict overall survival of the patients with breast and colorectal carcinoma.* Immuno-Oncology Summit, Bostonas, JAV, 2019.
18. *Benefits of digital pathology.* 15th International Congress for Stereology and Image Analysis, Orhusas, Danija, 2019.
19. *Pathology image analytics: going beyond visual.* Image Analysis Training School (IATS), Viena, Austrija, 2019.
20. *Deciphering tissue microenvironment with imaging and analytics.* 15th European Congress on Digital Pathology, Varvikas, JK, 2019.
21. *Digital Pathology Analytics for Biomarker Assessment.* Cancer Immunotherapy Workshop, Ryga, Latvija, 2018.
22. *Tissue Pathology, Mining Deeper with Imaging and Analytics.* 162nd ICB Seminar, Varšuva, Lenkija, 2018.
23. *Getting Pathology Pixels to Work.* 14th European Congress of Digital Pathology, Helsinkis, Suomija, 2018.
24. *Tissue Pathology Analytics: Digging Out More.* UC Davis, Pathology Department, Sacramento Kanada, JAV, 2018.
25. *Reading IHC Slides: Can Machines Do Better Than Humans?* 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, Belfastas, JK, 2017.
26. *Digital Pathology - Getting Online.* 24th German Baltic Symposium and IAP Baltic Division meeting, Ryga, Latvija, 2017.
27. *HPV and cancer.* IncoNet EaP Twinning Grants Project, New Vision University, Tbilisis, Sakartvelas, 2016.
28. *Pathology Online - Ready To Use?* Leeds University Hospital, Department of Pathology, JK, 2017.
29. *Pathology Online - Ready To Use?* 4th Nordic Symposium on Digital Pathology, Linkopingas, Švedija, 2016.
30. *Comprehensive Immunohistochemistry: Digital, Analytical and Integrated.* XXXI International Congress of the International Academy of Pathology and 28th Congress of the European Society of Pathology, Kelnas, Vokietija, 2016.
31. *Comprehensive Immunohistochemistry: Digital, Analytical, Integrated.* AstraZeneca, Kembridžas, JK, 2016.
32. *Comprehensive Immunohistochemistry: Digital, Analytical, Integrated.* Brigham and Women's Hospital, Department of Pathology, Masačusetas, JAV, 2016.
33. *Automated Image Analysis of HER2 FISH Enables New Definitions of Genetic Heterogeneity in Breast Cancer Tissue.* 13th European Congress on Digital Pathology, Berlynas, Vokietija, 2016.
34. *Poster: Automated Image Analysis of HER2 FISH in Breast Cancer Tissue to Support Cell Heterogeneity,* 3rd Nordic Symposium on Digital Pathology, Linkopingas, Švedija, 2015.
35. *Poster: Comprehensive Ki67 Immunohistochemistry in Breast Cancer Based on Hexagonal Tiling of Digital Image Analysis Data.* 22nd International Molecular Medicine Tri-Conference, San Franciskas, JAV, 2015.
36. *Digital Immunohistochemistry for Tissue-Based Diagnosis and Research: What Could and Should be Done?* Digital Pathology Congress, Londonas, JK, 2014.
37. *Digital Immunohistochemistry to Retrieve Novel Information on Biomarker Expression.* 26th European Congress of Pathology, Londonas, JK, 2014.
38. *Digital Immunohistochemistry Platform for the Staining Variation Monitoring Based on Integration of Image and Statistical Analyses with Laboratory Information System.* 12th European Congress on Digital Pathology, Paryžius, Prancūzija, 2014.
39. *Digital Immunohistochemistry Wizard: Image Analysis-Assisted Stereology Tool to Produce Reference Data Set for Calibration and Quality Control.* 12th European Congress on Digital Pathology), Paryžius, Prancūzija, 2014.
40. *Automated Image Analysis Enables Accurate Enumeration of the Ki-67 Labeling Index of Breast Cancer.* 25th European Congress of Pathology, Lisabona, Portugalija, 2013.
41. *Poster: A methodology to ensure and improve accuracy of Ki67 digital immunohistochemistry analysis in breast cancer tissue.* Advances in Breast Cancer Research: Genetics, Biology, and Clinical Application, San Antonio, Kanada, JAV, 2013.
42. *Digital Image Analysis for Better Accuracy in Pathology.* XXIX Congress of International Academy of Pathology, Keiptaunas, PAR, 2012.
43. *Perspectives of Routine Tissue-Based Diagnosis: Lean and Digital.* 24th European Congress of Pathology, Praha, Čekija, 2012.

44. *Digital Immunohistochemistry: New Horizons and Practical Solutions in Breast Cancer Pathology*. 11th European Congress on Telepathology and Virtual Microscopy, Venecija, Italija, 2012.
45. *Inter-Observer Variability and Evaluation of Automated Image Analysis Tools*. 23rd European Congress of Pathology, Helsikis, Suomija, 2011.
46. *Digital Image Analysis in Pathology: Benefits and Obligations*, 1st Congress of International Academy of Digital Pathology, Kvebekas, Kanada, 2011.
47. *The Results of Automated Image Analysis Workshop at the 10th European Congress on Telepathology and 4th International Congress on Virtual Microscopy*, Pathology Visions, San Diegas, Kanada, JAV 2010.

Projektai, dalyvavimas/vadovavimas:

- | | |
|-------------|---|
| 2021-2024 | Raumens neinfiltruojančio šlapimo pūslės urotelio vėžio atsako į BCG imunoterapiją numatymas panaudojant dirbtinį intelektą, LMT mokslininkų grupės, <i>Projekto vykdytojas</i> . |
| 2018-2021 | Gilaus konteksto audinių analizė integruotam navikų ir transplantuotų inkstų patologijos modeliavimui. Mokslinis tyrimas finansuojamas Europos socialinio fondo lėšomis pagal priemonės Nr. 09.3.3-LMT-K-712 veiklą „Mokslininkų kvalifikacijos tobulinimas vykdant aukšto lygio MTEP projektus“. |
| 2018 - 2022 | 2018- "Innovative Partnership for Action Against Cancer (iPAAC)", finansuojamas pagal ES Trečiąją sveikatos programą (Third Health Programme) 2014–2020; <i>Projekto vykdytojas</i> . |
| 2015-2018 | Projekto vadovas, „Nauji žymenys storosios žarnos vėžio individualizuotai terapijai: proteomika, mikroRNRomika, klinika“, LMT (199990 Eur). |
| 2013-2017 | Projekto vadovas, „Mokslo ir verslo bendradarbiavimas skaitmeninės patologijos srityje (Academia and Industry Collaboration for Digital Pathology (AIDPATH), FP7-PEOPLE-2013-IAPP, Marie Curie Actions – Industry-Academia Partnership and Pathways (IAPP))“ (3021689 Eur). |
| 2013-2015 | Projekto vadovas, „Išsamus biožymenų raiškos intranavikinio heterogeniškumo įvertinimas skaitmeninės imunohistochemijos vaizdo analizės būdu“, LMT, ES SF, Visuotinė dotacija (264739 Eur). |
| 2012-2014 | Vyriausiasis mokslo darbuotojas „Molekulinių žymenų komplekso, skirto prostatos vėžio klinikinio reikšmingumo įvertinimui, kūrimas“, LMT (222515 Eur). |
| 2010 | Projekto vadovas, „Žmogaus biologinių išteklių centras“ (parengtas LMT mokslo techninės infrastruktūros išplėstinis aprašas) (6371 Eur). |
| 2010–2011 | „Valstybinio patologijos centro pastato renovavimas, didinant energijos vartojimo efektyvumą“, Europos Sąjungos struktūrinės paramos lėšomis finansuotas projektas (988744 Eur). |
| 2009–2011 | „Santariškių medicinos įstaigų darbuotojų kvalifikacijos kėlimas“, Europos Sąjungos struktūrinės paramos lėšomis finansuotas projektas, SMĪA (284188 Eur (ES SF 218620 Eur, Lietuvos biudžeto 65568 Eur). |
| 2009–2012 | „Santara" mokslo slėnio programa (Jungtinio inovatyvios medicinos centro įsteigimas) (14770620 Eur, VPC dalis: 810936 Eur). |
| 2009–2010 | „Merkelio ląstelių poliomos viruso diagnostikos priemonių kūrimas“, LMT (23169 Eur). |
| 2008–2010 | Projekto vadovas, „SNOMED CT technologinės platformos sukūrimas Lietuvoje“, SAM Valstybės investicijų programa (724050 Eur). |
| 2008-2010 | Projekto vadovas, „Valstybinio patologijos centro kompetencijos stiprinimas vėžinių susirgimų ankstyvosios diagnostikos srityje“, Europos ekonominės erdvės ir Norvegijos finansiniai mechanizmai, Nacionalinė Norvegijos liginė, Oslo universitetas (426067 Eur). |
| 2007-2010 | „Telepatologijos tinklas Europoje“ (COST IC0604), su KTU (Informatikos katedra), 20 valstybių, 37 partneriai (28962 Eur). |
| 2007–2009 | „European Pathology Assessment & Learning System“ (EUROPALS) 15 valstybių, 30 partnerių (Europos patologijos departamentai ir institutai). Europos patologų atestavimo ir mokymosi sistemos sukūrimas (11584 Eur). |
| 2007–2009 | „Gimdos kaklelio ikivėžinės patologijos prognostinių veiksnių tyrimas panaudojant biolustų metodikas“ (10426 Eur). |
| 2007-2009 | „Priešinės liaukos ir krūties vėžio molekuliniai žymenys sistemos kūrimas“, Lietuvos valstybinis mokslo ir studijų fondas (66033 Eur). |
| 2006-2008 | Medicinos fizikos ir nanofotonikos aukštųjų studijų realizacija, ES (2858597 Eur). |
| 2006-2008 | Medicinos fizikinių technologijų ir nanofotonikos mokslo ir studijų centras (1894939 Eur). |
| 2005-2007 | Intrakranijinės aneurizmos modelių angiografiniams tyrimams kūrimo studija, EUREKA, Lietuvos valstybinis mokslo ir studijų fondas. |

Kvalifikacijos kėlimas:

- | | |
|------|---|
| 2017 | Mokymų programa „Design thinking inovacijų metodologijos principai ir įrankiai“ |
|------|---|

2016	Seminaras “Vadovavimas skirtingoms asmenybėms - charakteriai kine ir organizacijoje”
2011	Kursas “ <i>LEAN Management</i> ” (<i>Richard Zarbo, Henry Ford Healthcare System</i>)
2011	Seminaras Projektų rengimas ir valdymas (<i>Chmieliauskas ir Ramonas</i>)
2011	Seminaras Vadovavimo ir lyderiavimo įgūdžiai (<i>Franklin Covey</i>)
2011	Seminaras 7 įpročiai vadovams (<i>Franklin Covey</i>)
2011	Seminaras Personalo valdymas (<i>Franklin Covey</i>)
2011	Seminaras Padalinio vadovas (<i>Franklin Covey</i>)
2010	Strateginis ir metinis veiklos planavimas (Naujų galimybių studija)
2010	<i>Solutions focus programme</i> (<i>Mark Mc Kergow and Jenny Clark</i>)
2010	Konferencija-seminaras Molekulinė patologija diagnozei ir gydymui
2009	Ankstyvo krūties vėžio patologija, diagnozė ir gydymas
2009	Konferencija „Gimdos kaklelio vėžio prevencija ir ikivėžinių gimdos kaklelio būklių diagnostika“
2009	<i>Nottingham Image Analysis Training School</i> (<i>The University of Nottingham</i>)
2009	Mokslinė praktinė konferencija „Ankstyva kolorektalinio vėžio patologijos diagnostika“ (VU)
2008	<i>Quantitative immunohistochemistry in Digital Pathology</i> su COST action ICO0604 „ <i>Telepathology Network in Europe</i> “
2008	Mokslinė praktinė konferencija Gimdos kaklelio ikivėžinių susirgimų diagnostikos kokybės gerinimas (su VU)
2008	Procesų inovacijos konkurenciniam pranašumui (BMI)
2008	<i>9th European Congress of Telepathology and 3rd international congress on virtual microscopy</i>
2008	Third workshop of the open European Nephrology Science center (OpEN.SC) (<i>Institut fur Pathologie</i>)
2008	Robino Sharma seminaras „Lyderystės pamokos“ (Viva Persona)
2007	Motyvacijos alchemija: kaip pažadinti „miegančią“ iniciatyvą (BMI)
2007	<i>Management of Project-oriented Company</i> (ISM)
2007	Mokymo kursas Amerikos medicinos įstaigų finansų ir turto valdymas: Medicinos verslo plėtros galimybės Amerikoje (Ekonomikos mokymo centras)
2007	Workshop “ <i>European Tissuebanking for Medical research</i> ” (<i>The Erasmus Postgraduate School of Molecular Medicine, Rotterdam</i>)
2007	<i>Seminar on Early diagnosis of cervical cancer, breast cancer and colorectal cancer</i> (<i>Medical Knowledge institute</i>)
2002	<i>Managing Your Self</i> (<i>Jagdish Parikh</i>)

PUBLIKACIJOS

<https://www.webofscience.com/wos/author/record/F-9039-2012>

<https://orcid.org/0000-0001-9232-1730>

https://www.researchgate.net/profile/Arvydas_Laurinavicius

Clarivate Analytics *h*-index: 23

1. Kielaitė-Gulla, Aistė; Stulpinas, Rokas; Grigonytė, Agnė; Žilėnaitė-Petrulaitienė, Dovilė; Rasmusson, Allan; Laurinavičius, Arvydas; Strupas, Kęstutis. Overall survival prediction by tumor microenvironment lymphocyte distribution in hepatocellular carcinoma after liver transplantation // *Journal of surgical research*. San Diego, CA : Academic Press Inc Elsevier Science. ISSN 0022-4804. eISSN 1095-8673. 2024, vol. 295, p. 457-467.
2. Stulpinas, Rokas; Morkūnas, Mindaugas; Rasmusson, Allan; Drachneris, Julius; Augulis, Renaldas; Kielaitė-Gulla, Aistė; Strupas, Kęstutis; Laurinavičius, Arvydas. Improving HCC prognostic models after liver resection by AI-extracted tissue fiber framework analytics // *Cancers*. Basel : MDPI AG. eISSN 2072-6694. 2024, vol. 16, iss. 1, art. no. 106, p. [1-18].
3. Stulpinas R, Zilenaite-Petrulaitiene D, Rasmusson A, Gulla A, Grigonyte A, Strupas K, **Laurinavicius A**: Prognostic Value of CD8+ Lymphocytes in Hepatocellular Carcinoma and Perineoplastic Parenchyma Assessed by Interface Density Profiles in Liver Resection Samples. *Cancers* (Basel) 2023, 15.
4. Hashimoto D, Gulla A, Sato S, Yamamoto T, Yamaki S, Matsui Y, Ohe C, Yamasaki M, Hamada M, Ikeura T, Shimatani M, Breugelmans R, Utkus A, Poskus T, Samuilis A, Miglinas M, **Laurinavicius A**, Tomoda K, Hendrixson V, Sekimoto M, Strupas K: The academic impact and value of an international online surgery lecture series. *Surg Today* 2023.

5. Drachneris J, Rasmusson A, Morkunas M, Fabijonavicius M, Cekauskas A, Jankevicius F, **Laurinavicius A**: CD8+ Cell Density Gradient across the Tumor Epithelium-Stromal Interface of Non-Muscle Invasive Papillary Urothelial Carcinoma Predicts Recurrence-Free Survival after BCG Immunotherapy. *Cancers (Basel)* 2023, 15.
6. Yousif M, van Diest PJ, **Laurinavicius A**, Rimm D, van der Laak J, Madabhushi A, Schnitt S, Pantanowitz L: Artificial intelligence applied to breast pathology. *Virchows Archiv* 2022, 480:191-209.
7. Popova A, Racenis K, Kuzema V, Saulite AJ, Saulite M, Broks R, Oleinika K, Slisere B, Petersons A, **Laurinavicius A**, Cernevskis H, Lejnieks A, Kroica J: Leucine-Rich Alpha-2-Glycoprotein as a Potential Marker of Mesangial Cell Proliferation in Immunoglobulin A Nephropathy. *Nephrology Dialysis Transplantation* 2022, 37:I293-I.
8. Plancoulaine B, Rasmusson A, Labbe C, Levenson R, **Laurinavicius A**: A new approach for microstructure imaging. *Sci Rep* 2022, 12:19565.
9. Cerkauskaite A, Savige J, Janonyte K, Jeremiciute I, Miglinas M, Kazenaite E, **Laurinavicius A**, Strupaite-Sileikiene R, Vainutiene V, Burnyte B, Jankauskiene A, Rolfs A, Bauer P, Schroeder S, Cerkauskiene R: Identification of 27 Novel Variants in Genes COL4A3, COL4A4, and COL4A5 in Lithuanian Families With Alport Syndrome. *Front Med-Lausanne* 2022, 9.
10. Azukaitis K, Besusparis J, **Laurinavicius A**, Jankauskiene A: Case Report: SARS-CoV-2 Associated Acute Interstitial Nephritis in an Adolescent. *Front Pediatr* 2022, 10.
11. Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai YL, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Buikema H, Chang MC, Dietz RL, Dodson A, Fineberg S, Focke CM, Gao DX, Gown AM, Gutierrez C, Hartman J, Kos Z, Laenkholm AV, **Laurinavicius A**, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Salgado R, Sugie T, van der Vegt B, Viale G, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL, Grp BI, BIG-NAB NABCG: Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. *Modern Pathology* 2022.
12. Yousif M, van Diest PJ, **Laurinavicius A**, Rimm D, van der Laak J, Madabhushi A, Schnitt S, Pantanowitz L: Artificial intelligence applied to breast pathology. *Virchows Arch* 2021.
13. Vitkunaite A, Laurinaviciene A, Plancoulaine B, Rasmusson A, Levenson R, Shribak M, **Laurinavicius A**: Intranuclear birefringent inclusions in paraffin sections by polychromatic polarization microscopy. *Sci Rep* 2021, 11:6275.
14. Radziuviene G, Rasmusson A, Augulis R, Grineviciute RB, Zilenaite D, Laurinaviciene A, Ostapenko V, **Laurinavicius A**: Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients. *Front Oncol* 2021, 11:774088.
15. Morkunas M, Zilenaite D, Laurinaviciene A, Treigys P, **Laurinavicius A**: Tumor collagen framework from bright-field histology images predicts overall survival of breast carcinoma patients. *Sci Rep* 2021, 11:15474.
16. Mastaviciute A, Kilaite J, Petroska D, **Laurinavicius A**, Tamulaitiene M, Alekna V: Associations between Physical Function, Bone Density, Muscle Mass and Muscle Morphology in Older Men with Sarcopenia: A Pilot Study. *Medicina (Kaunas)* 2021, 57.
17. **Laurinavicius A**, Rasmusson A, Plancoulaine B, Shribak M, Levenson R: Machine-learning-based evaluation of intratumoral heterogeneity and tumor-stroma interface for clinical guidance. *Am J Pathol* 2021.
18. Dulskas A, Poskus T, Kildusiene I, Patasius A, Stulpinas R, **Laurinavicius A**, Masalaite L, Milaknyte G, Stundiene I, Venceviciene L, Strupas K, Samalavicius NE, Smailyte G: National Colorectal Cancer Screening Program in Lithuania: Description of the 5-Year Performance on Population Level. *Cancers (Basel)* 2021, 13.
19. Budginaite E, Morkunas M, **Laurinavicius A**, Treigys P: Deep Learning Model for Cell Nuclei Segmentation and Lymphocyte Identification in Whole Slide Histology Images. *Informatica* 2021, 32:23-40.
20. Bausys A, Senina V, Luksta M, Anglickiene G, Molnikaite G, Bausys B, Rybakovas A, Baltruskeviciene E, **Laurinavicius A**, Poskus T, Bausys R, Seinina D, Strupas K: Histologic Lymph Nodes Regression after Preoperative Chemotherapy as Prognostic Factor in Non-metastatic Advanced Gastric Adenocarcinoma. *J Cancer* 2021, 12:1669-77.
21. Zilenaite D, Rasmusson A, Augulis R, Besusparis J, Laurinaviciene A, Plancoulaine B, Ostapenko V, **Laurinavicius A**: Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma. *Front Oncol* 2020, 10:950.
22. Sablinskas V, Bandzeviciute R, Velicka M, Ceponkus J, Urboniene V, Jankevicius F, **Laurinavicius A**, Dasevicius D, Steiner G: Fiber ATR infrared spectroscopy of kidney tissue during live surgery. *Journal of biophotonics* 2020.

23. Rasmusson A, Zilenaite D, Nestarenkaite A, Augulis R, **Laurinavicius A**: Dataset for Immunogradient indicators for anti-tumor response assessment by automated tumor-stroma interface zone detection. 1.00 ed: Vilnius University, 2020.
24. Rasmusson A, Zilenaite D, Nestarenkaite A, Augulis R, Laurinaviciene A, Ostapenko V, Poskus T, **Laurinavicius A**: Immunogradient indicators for anti-tumor response assessment by automated tumor-stroma interface zone detection. *Am J Pathol* 2020.
25. Nestarenkaite A, Fadhil W, Rasmusson A, Susanti S, Hadjimichael E, Laurinaviciene A, Ilyas M, **Laurinavicius A**: Immuno-Interface Score to Predict Outcome in Colorectal Cancer Independent of Microsatellite Instability Status. *Cancers (Basel)* 2020, 12.
26. Gryguc A, Maciulaitis J, Mickevicius L, **Laurinavicius A**, Sutkeviciene N, Bumblyte IA, Maciulaitis R: Placenta derived stem cells for acute kidney injury treatment in a xenogeneic preclinical model. *Cytotherapy* 2020, 22:S203-S.
27. Bueno G, Gonzalez-Lopez L, Garcia-Rojo M, **Laurinavicius A**, Deniz O: Data for glomeruli characterization in histopathological images. *Data Brief* 2020, 29:105314.
28. Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai YL, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Borgquist S, Buikema H, Chang MC, Dietz RL, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao DX, Gown AM, Gutierrez C, Hartman J, Hugh JC, Kos Z, Laenkholm AV, **Laurinavicius A**, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Pantanowitz L, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Sakatani T, Salgado R, Spears M, Tarczynski JS, Sugie T, van der Vegt B, Viale G, Virk S, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL, Grp IKBCW, BIG-NABCG: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study. *Cancer Research* 2020, 80.
29. Sileikiene V, Laurinaviciene A, Lesciute-Krilaviciene D, Jurgauskiene L, Malickaite R, **Laurinavicius A**: Levels of CD4+ CD25+ T regulatory cells in bronchial mucosa and peripheral blood of chronic obstructive pulmonary disease indicate involvement of autoimmunity mechanisms. *Advances in Respiratory Medicine* 2019, 87:159-66.
30. Rimm DL, Leung SCY, McShane LM, Bai Y, Bane AL, Bartlett JMS, Bayani J, Chang MC, Dean M, Denkert C, Enwere EK, Galderisi C, Gholap A, Hugh JC, Jadhav A, Kornaga EN, **Laurinavicius A**, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, Hayes DF, Nielsen TO, Dowsett M: An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. *Mod Pathol* 2019, 32:59-69.
31. Joseph J, Roudier MP, Narayanan PL, Augulis R, Ros VR, Pritchard A, Gerrard J, **Laurinavicius A**, Harrington EA, Barrett JC, Howat WJ: Proliferation Tumour Marker Network (PTM-NET) for the identification of tumour region in Ki67 stained breast cancer whole slide images. *Sci Rep-Uk* 2019, 9.
32. Gasiule S, Dreize N, Kaupinis A, Razanskas R, Ciupas L, Stankevicius V, Kapustina Z, **Laurinavicius A**, Valius M, Vilkaitis G: Molecular Insights into miRNA-Driven Resistance to 5-Fluorouracil and Oxaliplatin Chemotherapy: miR-23b Modulates the Epithelial-Mesenchymal Transition of Colorectal Cancer Cells. *Journal of Clinical Medicine* 2019, 8.
33. Cerkauskaite A, Cerkauskiene R, Miglinas M, **Laurinavicius A**, Ding C, Rolfs A, Venceviciene L, Barysiene J, Kazenaite E, Sadauskiene E: Genotype-Phenotype Correlation in a New Fabry-Disease-Causing Mutation. *Med Lith* 2019, 55.
34. Abdelsamea MM, Pitiot A, Grineviciute RB, Besusparis J, **Laurinavicius A**, Ilyas M: A cascade-learning approach for automated segmentation of tumour epithelium in colorectal cancer. *Expert Syst Appl* 2019, 118:539-52.
35. Abdelsamea MM, Grineviciute RB, Besusparis J, Cham S, Pitiot A, **Laurinavicius A**, Ilyas M: Tumour Parcellation and Quantification (TuPaQ): a tool for refining biomarker analysis through rapid and automated segmentation of tumour epithelium. *Histopathology* 2019.
36. Morkunas M, Treigys P, Bernataviciene J, **Laurinavicius A**, Korvel G: Machine Learning Based Classification of Colorectal Cancer Tumour Tissue in Whole-Slide Images. *Informatica* 2018, 29:75-90.
37. Kukcinaviciute E, Jonusiene V, Sasnauskiene A, Dabkeviciene D, Eidenaitė E, **Laurinavicius A**: Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116. *Journal of Cellular Biochemistry* 2018, 119:5913-20.
38. Gallego J, Pedraza A, Lopez S, Steiner G, Gonzalez L, **Laurinavicius A**, Bueno G: Glomerulus Classification and Detection Based on Convolutional Neural Networks. *J Imaging* 2018, 4.
39. Abdelsamea MM, Pitiot A, Grineviciute RB, Besusparis J, **Laurinavicius A**, Ilyas M: A Novel Machine-Learning Approach for Segmentation of Tumour Epithelium in Colorectal Cancer. *Journal of Pathology* 2018, 246:S45.
40. Rimm DL, McShane LM, Leung SCY, Bai Y, Bane AL, Bartlett JMS, Bayani J, Chang MC, Dean M, Denkert C, Enwere E, Galderisi C, Gholap A, Hugh JC, Jadhav A, Kornaga E, **Laurinavicius A**, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, Hayes DF, Nielsen TO, Dowsett M: An

international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer. *Cancer Research* 2017, 77.

41. Radziuviene G, Rasmusson A, Augulis R, Lesciute-Krilaviciene D, Laurinaviciene A, Clim E, **Laurinavicius A**: Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue. *Biomed Res Int* 2017.
42. Mea VD, Carbone A, Di Loreto C, Bueno G, De Paoli P, Garcia-Rojo M, de Mena D, Gloghini A, Ilyas M, **Laurinavicius A**, Rasmusson A, Milione M, Dolcetti R, Pagani M, Stoppini A, Sulfaro S, Bartolo M, Mazzon E, Soyer HP, Pantanowitz L: Teaching Digital Pathology: The International School of Digital Pathology and Proposed Syllabus. *J Pathol Inform* 2017, 8:27.
43. Juozapaite S, Cerkauskiene R, **Laurinavicius A**, Jankauskiene A: The impact of IgM deposits on the outcome of Nephrotic syndrome in children. *BMC nephrology* 2017, 18.
44. Demidenko R, Daniunaite K, Bakavicius A, Sabaliauskaite R, Skeberdyte A, Petroska D, **Laurinavicius A**, Jankevicius F, Lazutka JR, Jarmalaite S: Decreased expression of MT1E is a potential biomarker of prostate cancer progression. *Oncotarget* 2017, 8:61709-18.
45. Barisoni L, Gimpel C, Kain R, **Laurinavicius A**, Bueno G, Zeng CH, Liu ZH, Schaefer F, Kretzler M, Holzman LB, Hewitt SM: Digital pathology imaging as a novel platform for standardization and globalization of quantitative nephropathology. *Clinical Kidney Journal* 2017, 10:176-87.
46. Riispere Z, **Laurinavicius A**, Kuudeberg A, Seppet E, Sepp K, Ilmoja M, Luman M, Kolvald K, Auerbach A, Ots-Rosenberg M: IgA nephropathy clinicopathologic study following the Oxford classification: Progression peculiarities and gender-related differences. *Medicina (Kaunas)* 2016, 52:340-8.
47. Pavyde E, Maciulaitis R, Mauricas M, Sudzius G, Didziokiene EI, **Laurinavicius A**, Sutkeviciene N, Stankevicius E, Maciulaitis J, Usas A: Skeletal Muscle-Derived Stem/Progenitor Cells: A Potential Strategy for the Treatment of Acute Kidney Injury. *Stem Cells Int* 2016.
48. **Laurinavicius A**, Plancoulaine B, Rasmusson A, Besusparis J, Augulis R, Meskauskas R, Herlin P, Laurinaviciene A, Muftah AAA, Miligy I, Aleskandarany M, Rakha EA, Green AR, Ellis IO: Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. *Virchows Archiv* 2016, 468:493-502.
49. **Laurinavicius A**, Plancoulaine B, Herlin P, Laurinaviciene A: Comprehensive Immunohistochemistry: Digital, Analytical and Integrated. *Pathobiology* 2016, 83:156-63.
50. Besusparis J, Plancoulaine B, Rasmusson A, Augulis R, Green AR, Ellis IO, Laurinaviciene A, Herlin P, **Laurinavicius A**: Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer. *Diagnostic Pathology* 2016, 11.
51. Ziedina I, **Laurinavicius A**, Jushinskis J, Suhorukov V, Malcevs A, Rozentals R: EFFICACY OF RITUXIMAB IN TREATMENT OF TRANSPLANT GLOMERULOPATHY. *Transplant International* 2015, 28:503.
52. Serenaite I, Daniunaite K, Jankevicius F, **Laurinavicius A**, Petroska D, Lazutka JR, Jarmalaite S: Heterogeneity of DNA methylation in multifocal prostate cancer. *Virchows Archiv* 2015, 466:53-9.
53. Plancoulaine B, Laurinaviciene A, Herlin P, Besusparis J, Meskauskas R, Baltrusaityte I, Iqbal Y, **Laurinavicius A**: A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data. *Virchows Archiv* 2015, 467:711-22.
54. Pavyde E, Maciulaitis R, Mauricas M, Sudzius G, Didziokiene EI, **Laurinavicius A**, Sutkeviciene N, Stankevicius E, Maciulaitis J, Usas A: Skeletal muscle-derived stem/progenitor cells: a potential strategy for the treatment of acute kidney injury. *Acta Physiologica* 2015, 215:8-9.
55. Maciulaitis J, Deveikyte M, Rekestyte S, Bratchikov M, Darinskas A, Simbelyte A, Daunoras G, Laurinaviciene A, **Laurinavicius A**, Gudas R, Malinauskas M, Maciulaitis R: Preclinical study of SZ2080 material 3D microstructured scaffolds for cartilage tissue engineering made by femtosecond direct laser writing lithography. *Biofabrication* 2015, 7.
56. **Laurinavicius A**, Green AR, Laurinaviciene A, Smailyte G, Ostapenko V, Meskauskas R, Ellis IO: Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma. *Oncotarget* 2015, 6:41134-45.
57. Kantauskaite M, Laucyte-Cibulskiene A, Miglinas M, **Laurinavicius A**: HISTOPATHOLOGICAL CLASSIFICATION FOR THE PREDICTION OF RENAL OUTCOME IN CRESCENTIC GLOMERULONEPHRITIS. *Nephrology Dialysis Transplantation* 2015, 30.
58. Demidenko R, Daniunaite K, **Laurinavicius A**, Lazutka JR, Jankevicius F, Jarmalaite S: Gene expression profile of recurrent prostate cancer. *BJU international* 2015, 116:6-7.

59. Brazdziute E, Miglinas M, Gruodyte E, Priluckiene J, Tamosaitis A, Bumblyte IA, Kuzminskis V, Burbaickaja S, Sakalauskiene M, Jankauskiene A, Cerkauskienė R, Pundziene B, **Laurinavicius A**: Nationwide renal biopsy data in Lithuania 1994-2012. *Int Urol Nephrol* 2015, 47:655-62.
60. Plancoulaine B, Laurinaviciene A, Meskauskas R, Baltrusaityte I, Besusparis J, Herlin P, **Laurinavicius A**: Digital immunohistochemistry wizard: image analysis-assisted stereology tool to produce reference data set for calibration and quality control. *Diagn Pathol* 2014, 9 Suppl 1:S8.
61. Mastaviciute A, Alekna V, Tamulaitiene M, **Laurinavicius A**, Petroska D, Strazdiene V: ASSOCIATION BETWEEN SKELETAL MUSCLE MORPHOMETRIC INDICES AND BODY COMPOSITION IN MEN WITH SARCOPENIA. *Osteoporosis Int* 2014, 25:S393.
62. **Laurinavicius A**, Plancoulaine B, Laurinaviciene A, Herlin P, Meskauskas R, Baltrusaityte I, Besusparis J, Dasevicius D, Elie N, Iqbal Y, Bor C, Ellis IO: A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. *Breast Cancer Research* 2014, 16.
63. Laurinaviciene A, Plancoulaine B, Baltrusaityte I, Meskauskas R, Besusparis J, Lesciute-Krilaviciene D, Raudeliunas D, Iqbal Y, Herlin P, **Laurinavicius A**: Digital immunohistochemistry platform for the staining variation monitoring based on integration of image and statistical analyses with laboratory information system. *Diagn Pathol* 2014, 9 Suppl 1:S10.
64. Galli R, Sablinskas V, Dasevicius D, **Laurinavicius A**, Jankevicius F, Koch E, Steiner G: Non-linear optical microscopy of kidney tumours. *Journal of biophotonics* 2014, 7:23-7.
65. Demidenko R, Daniunaite K, **Laurinavicius A**, Jankevicius F, Jarmalaite S, Lazutka JR: Investigation of potential biomarkers of biochemically recurrent prostate cancer. *Febs Journal* 2014, 281:481.
66. Daunoravicius D, Besusparis J, Zurauskas E, Laurinaviciene A, Bironaite D, Pankuweit S, Plancoulaine B, Herlin P, Bogomolovas J, Grabauskiene V, **Laurinavicius A**: Quantification of myocardial fibrosis by digital image analysis and interactive stereology. *Diagn Pathol* 2014, 9:114.
67. Daunoravicius D, Besusparis J, Zurauskas E, Laurinaviciene A, Bironaite D, Pankuweit S, Plancoulaine B, Herlin P, Bogomolovas J, Grabauskiene V, **Laurinavicius A**: Quantification of myocardial fibrosis by digital image analysis and interactive stereology. *Diagnostic Pathology* 2014, 9.
68. Daniunaite K, Stuopelyte K, Stankevicius V, **Laurinavicius A**, Jankevicius F, Jarmalaite S: Analysis of miRNA expression in prostate tumors and urine samples. *Febs Journal* 2014, 281:262-3.
69. Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, **Laurinavicius A**, Lazutka JR, Jankevicius F: Prognostic Value of RASSF1 Promoter Methylation in Prostate Cancer. *Journal of Urology* 2014, 192:1849-55.
70. Besusparis J, Jokubauskiene S, Plancoulaine B, Herlin P, Laurinaviciene A, Buivydiene A, **Laurinavicius A**: Quantification Accuracy of Liver Fibrosis by In Vivo Elastography and Digital Image Analysis of Liver Biopsy Histochemistry. *Analytical Cellular Pathology (Amsterdam)* 2014, 2014:317635.
71. Asoklis R, Kadziauskiene A, Paulaviciene R, Petroska D, **Laurinavicius A**: Quantitative histopathological assessment of ocular surface squamous neoplasia using digital image analysis. *Oncology letters* 2014, 8:1482-6.
72. Mastaviciute A, Alekna V, **Laurinavicius A**, Tamulaitiene M, Petroska D, Strazdiene V: RELATIONSHIP BETWEEN SKELETAL MUSCLE MASS, STRENGTH AND PHYSICAL PERFORMANCE IN ELDERLY MEN WITH SARCOPENIA. *Osteoporosis Int* 2013, 24:S242.
73. **Laurinavicius A**, Laurinaviciene A, Meskauskas R, Baltrusaityte I, Besusparis J, Herlin P, Plancoulaine B, Elie N, Belhomme P, Bor-Angelier C: Automated image analysis enables accurate enumeration of the Ki-67 labelling index of breast cancer. *Virchows Archiv* 2013, 463:101.
74. Yagi Y, Rojo MG, Kayser K, Kayser G, **Laurinavicius A**, Della Mea V, Levy B, Klossa J, Tearney G, Szymas J, Tsuchihashi Y, Tetu B: The First Congress of the International Academy of Digital Pathology: Digital pathology comes of age Introduction. *Analytical Cellular Pathology* 2012, 35:1-2.
75. Simanauskiene E, Daugelaviciene V, **Laurinavicius A**, Mickys U, Simonyte V, Vaitkeviciene G, Verkauskas G: Unilateral hydronephrosis and renal damage after acute leukemia. *Case Rep Med* 2012, 2012:968491.
76. Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, **Laurinavicius A**, Jankevicius F, Lazutka JR: Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer. *Genes Chromosomes & Cancer* 2012, 51:781-91.
77. **Laurinavicius A**, Raslavicus P: Consequences of "going digital" for pathology professionals - entering the cloud. *Stud Health Technol Inform* 2012, 179:62-7.
78. **Laurinavicius A**, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J: Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. *Diagnostic Pathology* 2012, 7.
79. **Laurinavicius A**, Laurinaviciene A, Dasevicius D, Elie N, Plancoulaine B, Bor C, Herlin P: Digital image analysis in pathology: Benefits and obligation. *Analytical Cellular Pathology* 2012, 35:75-8.

80. Garcia-Rojo M, Daniel C, **Laurinavicius A**: SNOMED CT in pathology. *Stud Health Technol Inform* 2012, 179:123-40.
81. Daniel C, Booker D, Beckwith B, Della Mea V, Garcia-Rojo M, Havener L, Kennedy M, Klossa J, **Laurinavicius A**, Macary F, Punys V, Scharber W, Schrader T: Standards and specifications in pathology: image management, report management and terminology. *Stud Health Technol Inform* 2012, 179:105-22.
82. Cortese R, Kwan A, Lalonde E, Bryzgunova O, Bondar A, Wu Y, Gordevicius J, Park M, Oh G, Kaminsky Z, Tverkuviene J, **Laurinavicius A**, Jankevicius F, Sendorek DHS, Haider S, Wang S-C, Jarmalaite S, Laktionov P, Boutros PC, Petronis A: Epigenetic markers of prostate cancer in plasma circulating DNA. *Human Molecular Genetics* 2012, 21:3619-31.
83. Sablinskas V, Urboniene V, Ceponkus J, **Laurinavicius A**, Dasevicius D, Jankevicius F, Hendrixson V, Koch E, Steiner G: Infrared spectroscopic imaging of renal tumor tissue. *J Biomed Opt* 2011, 16.
84. Laurinaviciene A, Dasevicius D, Ostapenko V, Jarmalaite S, Lazutka J, **Laurinavicius A**: Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays. *Diagnostic Pathology* 2011, 6.
85. Hufnagel P, Schrader T, Rojo G, **Laurinavicius A**, Kayser G: Demands on scanner developments based on technical and human tests. *Virchows Archiv* 2011, 459:S314-S5.
86. Garcia Rojo M, **Laurinavicius A**, Punys V, Gehring S: Encoding pathology diagnosis with SNOMED CT: feasibility of migration from SNOMED II to SNOMED CT. *Virchows Archiv* 2011, 459:S309.
87. Daniunaite K, Berezniakovas A, Jankevicius F, **Laurinavicius A**, Lazutka JR, Jarmalaite S: Frequent Methylation of RASSF1 and RARB in Urine Sediments From Patients with Early Stage Prostate Cancer. *Med Lith* 2011, 47:147-53.
88. Daniel C, Macary F, Garcia Rojo M, Klossa J, **Laurinavicius A**, Beckwith BA, Della Mea V: Recent advances in standards for collaborative Digital Anatomic Pathology. *Diagnostic Pathology* 2011, 6.
89. Brazdziute E, **Laurinavicius A**: Digital pathology evaluation of complement C4d component deposition in the kidney allograft biopsies is a useful tool to improve reproducibility of the scoring. *Diagnostic Pathology* 2011, 6.
90. Rimiene J, Petronyte J, Gudleviciene Z, Smailyte G, Krasauskaite I, **Laurinavicius A**: A Shandon PapSpin liquid-based gynecological test: A split-sample and direct-to-vial test with histology follow-up study. *Cytojournal* 2010, 7.
91. Punys V, **Laurinavicius A**, Puniene J, Adlassnig K, Blobel B, Mantas J, Masic I: A Data Model for Handling Whole Slide Microscopy Images in Picture Archiving and Communications Systems. *Medical Informatics in a United and Healthy Europe* 2009, 150:856-60.
92. Punys V, **Laurinavicius A**, Puniene J: A data model for handling whole slide microscopy images in picture archiving and communications systems. *Stud Health Technol Inform* 2009, 150:856-60.
93. Jankevicius F, Jarmalaite S, Sabaliauskaite R, Kalinauskaite N, Dasevicius D, **Laurinavicius A**, Lazutka J: TMPRSS2: ERG gene fusion and epigenetic changes in tumour suppressor genes are associated with clinical markers of poor prognosis in prostate cancer patients. *Eur Urol Suppl* 2009, 8:573.
94. Zurauskas E, Usinskiene J, Gaigalaite V, Blanc R, Usinskas A, **Laurinavicius A**: [Models of intracranial aneurysms for angiographic imaging modalities. A technical note]. *Medicina (Kaunas)* 2007, 43:562-7.
95. Maslauskiene R, Bumblyte IA, Sileikiene E, Grazulis S, **Laurinavicius A**, Pleckaitis M, Alekniene D, Dobrovolskiene R, Vainauskas V, Juodeikiene L, Steckis R, Sakalauskiene M, Macius K, Urbanaviciene J, Labutiene V, Gaupsiene E, Ziaukiene G, Burbaickaja S, Gailiunas J: [The prevalence of Fabry's disease among male patients on hemodialysis in Lithuania (a screening study)]. *Medicina (Kaunas)* 2007, 43 Suppl 1:77-80.
96. Beitnaraitė S, Kovaliunas E, **Laurinavicius A**: [Primary glomerulopathies in Lithuania: a retrospective analysis of renal biopsy cases (2000-2006)]. *Medicina (Kaunas)* 2007, 43 Suppl 1:6-10.
97. Razukeviciene L, Bumblyte I, Kuzminskis V, **Laurinavicius A**: Membranoproliferative glomerulonephritis is still the most frequent glomerulonephritis in Lithuania. *Clinical Nephrology* 2006, 65:87-90.
98. Kaltenis P, Schumacher V, Jankauskiene A, **Laurinavicius A**, Royer-Pokora B: Slow progressive FSGS associated with an F392L WT1 mutation. *Pediatric Nephrology* 2004, 19:353-6.
99. Jankauskiene S, Zurauskas E, Laurinaviciene A, Vaisnyte B, Barkauskas E, Kucinskiene Z, **Laurinavicius A**, Triponis V: Detection of Chlamydia pneumoniae and cytomegalovirus in atherosclerotic tissue and investigation of serological status of patients with chronic atherosclerosis in Lithuanian population. *Atherosclerosis Supp* 2004, 5:14-5.
100. Jankauskiene S, Zurauskas E, Laurinaviciene A, Vaisnyte B, Barkauskas E, Kucinskiene Z, **Laurinavicius A**: Detection of Chlamydia pneumoniae in atherosclerotic tissue and investigation of serological status in patients with chronic atherosclerosis. *Atherosclerosis Supp* 2004, 5:125.

101. Razukeviciene L, Kuzminskis V, Bumblyte IA, **Laurinavicius** A: [The indications of renal biopsies and spectrum of renal diseases in five nephrological centers of Lithuania (a five-year study)]. *Medicina (Kaunas)* 2003, 39 Suppl 1:1-8.
 102. Razukeviciene L, Kuzminskis V, Bumblyte IA, **Laurinavicius** A: [Prognosis of chronic renal failure in patients with membranous nephropathy]. *Medicina (Kaunas)* 2003, 39 Suppl 1:9-15.
 103. Rainiene T, Papinigiene L, **Laurinavicius** A: [Nephrotoxicity of cyclosporin A after kidney transplantation]. *Medicina (Kaunas)* 2003, 39 Suppl 1:161-5.
 104. **Laurinavicius** A, Gruodyte E, Priluckiene J, Razukeviciene L, Supranaviciene L, Salkus G: [Potential causes of antigenemia in the patients with an immune complex-mediated membranoproliferative glomerulonephritis in Lithuania]. *Medicina (Kaunas)* 2003, 39 Suppl 1:28-32.
 105. Furness P, Taub N, Assmann K, Banfi G, Cosyns J, Dorman A, Hill C, Kapper S, Waldherr R, **Laurinavicius** A, Marcussen N, Martins A, Nogueira M, Regele H, Seron D, Carrera M, Sund S, Taskinen E, Paavonen T, Tihomirova T, Rosenthal R: International variation in histologic grading is large, and persistent feedback does not improve reproducibility. *American Journal of Surgical Pathology* 2003, 27:805-10.
 106. **Laurinavicius** A, Rennke HG: Collapsing glomerulopathy - A new pattern of renal injury. *Seminars in Diagnostic Pathology* 2002, 19:106-15.
 107. Jankauskiene A, Druskis V, **Laurinavicius** A: Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration. *Clinical Nephrology* 2001, 56:S27-S9.
 108. Pependikyte V, **Laurinavicius** A, Paterson A, Macciardi F, Kennedy J, Petronis A: DNA methylation at the putative promoter region of the human dopamine D2 receptor gene. *Neuroreport* 1999, 10:1249-55.
 109. Petronis A, Pependikyte V, Kennedy J, **Laurinavicius** A: DNA methylation analysis of the putative promoter region of the dopamine D2 receptor gene in postmortem brains of schizophrenia patients and controls. *Schizophr Res* 1999, 36:100-1.
 110. **Laurinavicius** A, Hurwitz S, Rennke H: Collapsing glomerulopathy in HIV and non-HIV patients: A clinicopathological and follow-up study. *Kidney International* 1999, 56:2203-13.
-